CADL: Candel Therapeutics, Inc.
Performance
CADL +88.29%
Watchlist
Select an item
Summary
CADL at a glance
CADL returned +88.29% over the past year and -2.58% a year over five years. Its worst drop in that year was -43.35%, smaller than 32% of stocks on Redstone, and its Sharpe ratio of 1.18 beats 83% of stocks on Redstone. It pays no dividends.
Current Drawdown
-30.98%
Rolling Volatility
85.02%
Actions
Metrics
Risk Indicators
Alpha65.17%
Beta2.08x
Sharpe1.18
Sortino1.95
Omega1.23
Calmar2.04
Martin5.04
Profile
About CADL
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $726M
- Listed
- Jul 2021
- Employees
- 55
- Headquarters
- Needham, MA
- Website
- candeltx.com
Comparisons